- AstraZeneca and US rival Bristol Myers Squibb have reportedly held discussions regarding a potential merger, which could create a pharmaceutical giant valued at over £300 billion.
- Such a tie-up would establish the world's fourth-largest pharmaceutical company, though sources indicate the deal's progression is uncertain and could face delays or collapse.
- The proposed merger is expected to face significant regulatory hurdles, particularly from the Trump administration's antitrust authorities, who have sought to increase domestic investment.
- Cambridge-based AstraZeneca, with a market value of approximately £196 billion, is seeking to expand its presence in the US, while New York-listed BMS is valued at around £133 billion.
- An analyst noted that despite AstraZeneca's previous statements about not needing mergers and acquisitions, a deal with BMS could face challenges due to their large, overlapping cancer divisions.
IN FULL
